Key Takeaways Shares of Insulet and DexCom, which provide devices for patients with diabetes, were the weakestperforming S&P 500 stocks on Tuesday. The losses for the medtech stocks came after Eli Lilly said its blockbuster drug effectively reduced the risk of patients developing type 2 diabetes. Insulet and DexCom have been navigating headwinds related to their user growth outlook. Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled ...